Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act

Eli Lilly CEO Touts Eloralintide's Superiority in Obesity Battle

Eli Lilly CEO David Ricks has positioned the company's investigational obesity drug, eloralintide, as superior to rival amylin assets from companies like AbbVie and Pfizer. Ricks stated that eloralintide, a selective amylin receptor agonist, is designed to avoid gastrointestinal side effects by "dialing out" the calcitonin receptor, unlike competitors' dual amylin and calcitonin receptor agonists (DACRAs). In a Phase 2 trial, eloralintide demonstrated a 12-1 bias for amylin over calcitonin and achieved 20% weight loss at 48 weeks. The drug has now advanced to a registrational Phase 3 trial, with Lilly also exploring its combination with tirzepatide.

• Eli Lilly's eloralintide is highlighted as a selective amylin receptor agonist, distinct from competitors' dual amylin and calcitonin receptor agonists (DACRAs). CEO David Ricks emphasized that Lilly's molecule has "dialed out" the calcitonin receptor, which he suggests drives better efficacy by avoiding common gastrointestinal side effects and simplifying titration compared to DACRAs.
• In a Phase 2 clinical trial, eloralintide demonstrated significant efficacy, achieving 20% weight loss at 48 weeks. This strong performance is a key factor in Lilly's confidence that the drug will become a major product in the burgeoning obesity market, leading to its progression into a registrational Phase 3 trial.
• Lilly is strategically exploring a combination approach for eloralintide with its blockbuster drug tirzepatide (Zepbound/Mounjaro) to further enhance weight loss outcomes. This strategy, coupled with Ricks's public statements challenging rivals' approaches, underscores Lilly's aggressive positioning and high expectations for eloralintide in the competitive obesity pipeline.

Eloralintide's Phase 2 Efficacy and Selective Amylin Agonism

Recent clinical trials have demonstrated substantial efficacy for tirzepatide across multiple randomized controlled studies. Nine RCTs encompassing 7,111 participants with ages ranging from 36.1 to 65.25 years evaluated tirzepatide as a once-weekly injection at doses from 5 mg to 15 mg. At medium-term follow-up (12-18 months), tirzepatide achieved a mean percentage reduction in body weight of -16.03% (95% CI -18.91 to -13.14), with participants showing dose-dependent weight loss ranging from 9 kg at the 5 mg dose to 12 kg at the 15 mg dose at 6 months. The proportion of participants achieving ≥5% weight reduction demonstrated a relative risk of 3.60 (95% CI 2.44 to 5.30) compared to controls. Long-term efficacy at 3.5 years remained robust with mean percentage weight reduction of -15.66% (95% CI -19.14 to -12.18).

Safety outcomes for tirzepatide revealed increased non-serious adverse events at medium-term with RR 1.33 (95% CI 1.03 to 1.71), while serious adverse events showed uncertain evidence with RR 0.99 (95% CI 0.88 to 1.12). Adverse events leading to withdrawal occurred more frequently with tirzepatide (RR 2.06, 95% CI 1.21 to 3.52), though major adverse cardiovascular events showed little difference from controls (RR 0.75, 95% CI 0.34 to 1.66). Mortality rates demonstrated no significant difference (RR 0.79, 95% CI 0.34 to 1.83). Long-term safety profiles showed improved tolerability with non-serious adverse events at RR 1.05 (95% CI 0.98 to 1.11) and adverse events leading to withdrawal at RR 1.64 (95% CI 0.97 to 2.76).

Comparative effectiveness studies demonstrated tirzepatide's superiority over existing GLP-1 receptor agonists. In network meta-analyses comparing tirzepatide to semaglutide 2.4 mg, the 15 mg dose of tirzepatide outperformed semaglutide, while lower doses (5 mg and 10 mg) did not show superiority. A comprehensive Cochrane review of liraglutide involving 24 RCTs with 9,937 participants aged 31.3 to 64.7 years demonstrated more modest efficacy, with medium-term percentage weight change of -4.72% (95% CI -5.32 to -4.12) and participants achieving ≥5% weight reduction at RR 2.10 (95% CI 1.80 to 2.45). Liraglutide's safety profile showed increased adverse events leading to withdrawal (RR 1.98, 95% CI 1.30 to 3.02) but favorable cardiovascular outcomes with MACE showing RR 0.86 (95% CI 0.66 to 1.10).

Differentiating Eloralintide in the Amylin Agonist Pipeline

Eloralintide is a long-acting amylin analogue that acts as an amylin receptor (AMYR) agonist, demonstrating strong efficacy as monotherapy in clinical trials for obesity and type 2 diabetes. Several other compounds with similar mechanisms of action are advancing through clinical development for these indications. However, specific intervention model data for these trials was not available in the literature reviewed.

Eloralintide's Path to Phase 3 and Combination Strategies

Recent clinical trials are exploring diverse combination therapy approaches for obesity treatment, ranging from innovative pharmacological combinations to integrated lifestyle interventions. Tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated sustained efficacy when combined with weight-inducing medications across the SURMOUNT trial series. Post hoc analyses revealed that approximately one-fifth of participants used concomitant weight-inducing medications, with tirzepatide achieving substantial weight reductions of -13.3% to -21.3% in SURMOUNT-1, -26.1% in SURMOUNT-3, and -18.6% in SURMOUNT-4 compared to placebo. Additionally, tirzepatide is being investigated in combination with standard fertility-sparing treatments for obese patients with endometrial cancer and atypical hyperplasia, targeting both oncological outcomes and metabolic parameters in a phase II trial enrolling 45 patients.

Lifestyle-based combination approaches are gaining prominence in obesity management strategies. The REPAIR trial is evaluating a comprehensive plant-based intensive lifestyle intervention combining a 12-week total diet meal replacement phase with a 40-week maintenance phase incorporating structured exercise and behavioral change curricula. This multi-component approach targets both diabetes remission and significant weight loss (≥15%) in adults with early-onset type 2 diabetes and obesity. Time-restricted eating combined with calorie restriction represents another emerging dietary strategy, with clinical evidence demonstrating 3-5% body weight reduction, 0.3-0.5% improvement in glycated hemoglobin, and 6-7% reduction in total cholesterol.

Fixed-dose pharmaceutical combinations are also showing promise in addressing the complex metabolic profile of obesity-related comorbidities. The empagliflozin-linagliptin combination has demonstrated significant metabolic benefits in SGLT2 inhibitor-naïve patients with type 2 diabetes, achieving 1.5% HbA1c reduction and 3.3 kg weight loss over 12 months. These combination strategies reflect the evolving understanding that obesity requires multi-target therapeutic approaches addressing both weight management and associated metabolic dysfunction.

Selective Amylin Agonist Poised to Reshape Obesity Treatment

The recent announcement regarding Eli Lilly's investigational obesity drug, eloralintide, marks a significant moment in the rapidly evolving landscape of metabolic disease pharmacotherapy. With Phase 2 data demonstrating an impressive 20% weight loss at 48 weeks, eloralintide, a selective amylin receptor agonist, is poised to become a formidable contender in a market increasingly defined by highly efficacious anti-obesity medications. This level of weight reduction is comparable to, and in some cases exceeds, the efficacy observed with leading dual incretin agonists like tirzepatide, which has shown 15-21% weight loss in various trials.

What truly differentiates eloralintide, however, is its targeted mechanism. By selectively activating the amylin receptor while "dialing out" the calcitonin receptor, Lilly aims to mitigate the gastrointestinal side effects—such as nausea, vomiting, and diarrhea—that are commonly associated with both dual amylin and calcitonin receptor agonists (DACRAs) and many incretin-based therapies. Improved tolerability is a critical factor for long-term patient adherence in chronic conditions like obesity, and if this selective approach translates to a significantly better patient experience in Phase 3, it could carve out a substantial market niche.

Eli Lilly's strategic intent is clear: to solidify its leadership in metabolic health. The advancement of eloralintide to a registrational Phase 3 trial, coupled with plans to explore its combination with tirzepatide, suggests a multi-pronged approach to maximize patient outcomes and market share. A combination therapy could potentially unlock synergistic benefits, leading to even greater weight loss or broader metabolic improvements, further raising the bar for obesity treatment.

However, the path forward is not without its challenges. While eloralintide's Phase 2 data indicated general tolerability, higher doses still reported notable rates of nausea and fatigue, underscoring the need for careful monitoring in larger Phase 3 populations. The competitive landscape is also intensifying, with other dual and triple incretin agonists demonstrating remarkable efficacy, some achieving over 20% weight loss. Lilly will need to clearly articulate eloralintide's unique value proposition, particularly regarding its tolerability profile, to stand out. Furthermore, the development and market acceptance of combination therapies, while promising, introduce complexities around dosing, potential additive side effects, and cost-effectiveness that will require robust clinical validation. The future of obesity management is increasingly personalized, and drugs like eloralintide, with their refined mechanisms, represent the next wave of innovation.